Nomogram Models Based on the Gene Expression in Prediction of Breast Cancer Bone Metastasis

Table 3

Cox regression analysis of the GESBN models and clinical variables in the validation cohorts.

Overall survival
Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
N stage	0.856 (0.388–1.887)	0.700	0.761 (0.343–1.687)	0.501
Grade	1.210 (0.364–4.019)	0.756	1.198 (0.337–4.265)	0.780
T stage	1.696 (0.980–2.930)	0.059	1.407 (0.827–2.393)	0.208
Risk score	2.719 (1.300–5.686)	0.008	2.442 (1.130–5.227)	0.023
Progression-free survival
Grade	1.635 (0.792–3.374)	0.184	1.323 (0.535–3.272)	0.545
Age	1.022 (0.987–1.058)	0.227	1.037 (0.996–1.080)	0.074
PR status	0.333 (0.133–0.835)	0.019	0.572 (0.194–1.686)	0.311
Risk score	2.714 (1.582–4.655)	<0.001	2.773 (1.469–5.235)	0.002

abrAbbreviations. GESBN, gene expression signature-based nomogram; HR, hazard ratio; 95% CI, 95% confidence interval; PR status, progesterone receptor status.